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Abstract
Background A range of treatments for patients with severe hemophilia A (HA) have been developed over the last decade, 
allowing for reduced frequency of administration and improved outcomes (joint health and breakthrough bleeding rates). 
While clinically effective, the cost effectiveness of these treatments has not been established.
Objective This study presents a cost-effectiveness analysis of contemporary rFVIII treatments for severe HA patients without 
inhibitors.
Methods A published semi-Markov model was used to compare three different prophylaxis regimens: (1) extended half-
life (EHL) recombinant Factor VIII (rFVIII) Fc-fusion protein (rFVIIIFc,  Eloctate®, Sanofi), (2) EHL PEGylated rFVIII 
(PEG-rFVIII,  Adynovate®, Takeda), and (3) standard half-life (SHL) rFVIII (antihemophilic factor [recombinant],  Advate®, 
Takeda), used as a proxy for all SHL rFVIII treatments. Acquisition costs were included based on published dosing and 
weight data. Benefits were incorporated through published annualized bleeding rates, rates of target joint development/reso-
lution, and improvements in the modified hemophilia joint health score. Results were presented as total, discounted costs, 
and quality-adjusted life-years (QALYs).
Results rFVIIIFc was shown to provide the most QALYs (27.922) compared with both PEG-rFVIII (27.454) and SHL 
rFVIII (27.071), at lower costs. Discounted lifetime costs were estimated at US$18.235m (rFVIIIFc), US$20.198m (PEG-
rFVIII), and US$18.285m (SHL rFVIII), and were predominantly affected by model settings related to acquisition costs, 
patient weight, and dosing.
Conclusions rFVIIIFc may offer a cost-effective option for severe HA patients. Uncertainties owing to the limited evidence 
base is the main limitation of the study.
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1 Introduction
Hemophilia A (HA) is a rare genetic disorder caused by 
deficiencies in the clotting protein Factor VIII (FVIII). There 
are approximately 20,000 people in the US living with HA, 
with approximately 56.6% of cases termed ‘severe’ (defined 
as patients with an endogenous factor VIII coagulant activ-
ity [FVIII:C] level <1% of the ‘normal’ amount) [1, 2]. As 
HA is caused by mutation of the X chromosome, nearly all 
patients are male; however, in rare cases HA may also occur 
in females.
Patients with HA are at risk of life-threatening bleeding, 
particularly those with severe disease [2, 3]. Due to lower 
FVIII levels compared with healthy individuals, patients 
with severe HA (SHA) bleed for longer periods of time—
both externally (for example, due to trauma) or internally 
(predominantly into joints and muscles). Soft tissue (muscle) 
bleeding and hemarthroses (joint bleeding) in particular can 
be severely debilitating for patients with SHA, and are asso-
ciated with impaired mobility, a risk of developing arthropa-
thy (disease of the joint), and reduced quality of life [2–5].
Konkle et al. (2019) recently reviewed a range of clinical 
studies in hemophilia with the goal of identifying which 
outcomes are of most importance to patients and providers 
[6]. The authors of this study noted that traditional endpoints 
related to bleeding are of clear importance to both providers 
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Key Points for Decision Makers 
Prophylaxis with recombinant Factor VIII (rFVIII) has 
been shown to lead to substantial improvement in out-
comes for patients with hemophilia A compared with on-
demand use, though rFVIII consumption comprises the 
majority of costs in the management of this condition.
rFVIIIFc, an extended half-life rFVIII product, may 
provide cost savings and improve quality of life versus 
another extended half-life rFVIII product (PEG-rFVIII) 
and standard half-life rFVIII products, yet the differ-
ences in costs and effects versus these therapies remain 
uncertain.
This study illustrates that the key determinants of cost 
effectiveness in hemophilia A are related to product 
acquisition costs and how impacts on joint health trans-
late to changes in health-related quality of life.
products. EHL products may be administered less frequently 
while achieving similar FVIII:C levels compared with an 
SHL product. Alternatively, with EHL rFVIII products, 
patients may be treated at the same frequency and dose as 
with SHL rFVIII products, but are expected to spend less 
time below a given targeted endogenous FVIII:C level such 
that the risk of experiencing breakthrough bleeds is reduced.
The first FDA-approved EHL product was rFVIII Fc-
fusion protein (rFVIIIFc,  Eloctate®, Sanofi). The pivotal 
A-LONG study allowed patients to be treated with an indi-
vidualized regimen, every 3–5 days, in order to maintain 
appropriate FVIII:C levels (ClinicalTrials.gov identifier: 
NCT01181128, further information reported by Mahlangu 
et al. [10]). Individualized regimens can be tailored to a 
number of patient-specific considerations, such as bleed-
ing risk, pharmacokinetic profile, joint status, and physical 
activity/lifestyle [11].
Since the initial approval of rFVIIIFc in 2014 [12], other 
EHL FVIII products, such as PEGylated rFVIII (PEG-
rFVIII,  Adynovate®, Takeda) have been approved and shown 
to be associated with benefits in terms of reduced frequency 
of administration and lower annualized bleed rates (ABRs) 
versus SHL rFVIII treatment [10, 13]. The use of SHL ver-
sus EHL rFVIII products for the treatment of SHA patients 
over time was considered by Croteau et al. [14]. In this 
study, the authors found that over an 18-month period from 
mid-2016 to late 2017, EHL rFVIII use more than doubled, 
increasing from approximately 13% to 28% of patients [14].
To establish the relative value of treatments, cost-effec-
tiveness analysis (CEA) may be performed in order to com-
pare the costs and effects attributable to each treatment. This 
study presents the results of a CEA of potential rFVIII-based 
treatments for severe HA adult patients without inhibitors 
in the US. The aim of the study was to determine the cost 
effectiveness of these treatments, and to establish the key 
drivers of CEA results in this patient population. The CEA 
adopts a US healthcare payer perspective.
2  Methods
2.1  Analysis Scope
The population considered within the analysis was patients 
with severe HA without inhibitors, initiating prophylaxis 
from the age of 1 year. Three prophylaxis treatments were 
compared: (i) rFVIIIFc (EHL), (ii) PEG-rFVIII (EHL), and 
(iii) SHL rFVIII. For the purpose of this analysis, antihemo-
philic factor (recombinant)  (Advate®, Takeda) was assumed 
to represent a proxy for a range of SHL rFVIII products 
used in clinical practice. Alternative costs associated with 
other SHL rFVIII products were explored with sensitivity 
analyses.
and patients, especially when considering the link between 
joint bleeds and the preservation of joint health. However, 
bleeding episodes alone do not reflect the full impact of SHA 
on patients, and other measures (such as the development 
of complications and ability to perform usual activities) are 
also important to capture within contemporary trials.
The standard of care for patients with SHA in the US 
currently comprises prophylaxis using recombinant FVIII 
(rFVIII) replacement products for the prevention of bleeding 
episodes, plus episodic rFVIII treatment for the resolution 
of breakthrough bleeds.
Some patients may develop alloantibodies against exog-
enous FVIII (typically referred to as ‘inhibitors’), rendering 
rFVIII therapies ineffective, and so alternative treatments 
such as bypassing agents and other non-factor therapies may 
be used. However, the preferred outcome is to eliminate the 
inhibitor, for which immune tolerance induction may be 
needed.
Some patients may be treated with higher doses of rFVIII 
based upon the individual patient’s age, disease history, and 
level of physical activity. In spite of the different treatment 
options that may be used, the primary goals of treatment for 
patients with HA are twofold: first, to prevent or reduce the 
frequency of bleeding episodes; and second, to minimize the 
complications of bleeding, namely, to preserve joint health 
(i.e., to avoid further deterioration due to hemarthroses and/
or soft tissue bleeding) [6–9].
Since the introduction of rFVIII therapies in the US in the 
1990s, the treatment landscape for patients with SHA has 
evolved markedly. More recent rFVIII products have been 
described as having an extended half-life (EHL) compared 
with previously developed, ‘standard’ half-life (SHL) rFVIII 
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Outcomes of the analysis were expressed as total costs 
and quality-adjusted life-years (QALYs). The QALY is a 
composite measure that aims to incorporate both the health-
related quality and length of life. From these outcomes, the 
cost per QALY gained may be calculated (i.e., the incremen-
tal cost-effectiveness ratio [ICER]). Different treatments are 
expected to provide similar clinical benefits, which may lead 
to a difference in QALYs close to zero; however, costs are 
expected to differ.
In line with the reference case used in the Institute for 
Clinical and Economic Review’s assessment of emicizumab 
in the inhibitor population, the CEA adopted a lifetime hori-
zon, with a discount rate of 3% applied for both costs and 
health outcomes (i.e. QALYs). A model cycle length of 1 
year was used, with a half-cycle correction applied based on 
published guidance [15, 16].
2.2  Model Structure and Patient Population
The model used to inform this CEA builds on a previously 
used structure to assess the cost effectiveness of rFVIIIFc for 
Italian SHA patients [17]. The model structure was chosen 
based on the ability to capture the impact of treatment on 
joint health and translate this into both costs and outcomes 
within the model. The previous study did not include a com-
parison with PEG-rFVIII, yet the structure is aligned with 
commonly reported outcomes that are documented within 
published clinical studies (i.e., bleeding events and capturing 
the impact of joint disease) [6].
A three-state semi-Markov model was constructed in 
 Microsoft® Excel (Fig. 1). Patients were categorized by tar-
get joint1 (TJ) status at baseline, and transitions between 
health states were based on calculated rates of TJ develop-
ment or resolution. Transitions to death were based on age-
dependent background mortality rates.
Patient health-related quality of life (HRQoL) was cap-
tured within the model according to the number of bleeds 
per year (ABR), and whether or not the patient had TJ(s). 
Only treatment acquisition costs were included within the 
model (prophylaxis and episodic treatment), as all other 
costs were assumed to be similar between treatments.
All patients were assumed to be male, and at baseline 
68.5% were assumed to have pre-existing TJs (aligned with 
the A-LONG study population). The starting age of the 
cohort was set at 1 year, in line with the licensed indications 
for rFVIIIFc, PEG-rFVIII, and SHL rFVIII. In specifying a 
starting age of 1 year, differences in the longer-term costs 
and effects of treatment were captured as patients age.
2.3  Efficacy Inputs
The impact of treatment of patient outcomes was captured 
as a combination of impacts due to the frequency of break-
through bleeding episodes, and the impact on joint health. To 
capture the impact of bleeding episodes, ABRs were identi-
fied from published literature. The values used to inform the 
base-case analyses are presented in Table 1, with alternative 
values explored within sensitivity analysis. For consistency 
between the evidence sources, the median ABR associated 
with all reported bleeds was used for each regimen.
To capture the impact of treatments on joint health, 
probabilities were included within the model relating to 
the development or resolution of TJs. For simplicity, it was 
assumed that patients could not develop further TJs while 
receiving either rFVIIIFc or PEG-rFVIII, based on very few 
reports of TJ development in patients receiving EHL rFVIII 
treatment. However, for SHL rFVIII, a 9.87% probability of 
developing TJs per year was used [17].
For the resolution of TJs, further data are available. The 
probabilities used within the economic model (per annual 
model cycle) are
• rFVIIIFc: 99.15%, based on data from A-LONG (n = 233 
of 235 of TJs at baseline were resolved over a 12-month 
period) [19]
• PEG-rFVIII: 85.53%, based on data from Mullins et al., 
where n = 10 of 14 pediatric patients with TJs at baseline 
resolved one or more TJs within a 6-month period [20]
• SHL rFVIII: 73.33%, based on data from Panicker et al., 
which showed that 11 of 15 patients with TJs at baseline 
had no further TJ bleeds after at least 1 year of follow up 
[21]
As per the base-case settings for bleeding outcomes, 
alternative settings for joint outcomes were explored in 
sensitivity analysis. In reality, some bleeding episodes may 
be fatal, though this is expected to be a very small propor-
tion of bleeding events, thus mortality effects were omitted 
from the analysis. The model therefore assumes all deaths 
No TJs ≥1 TJ(s)
Dead
Fig. 1  Cost-effectiveness model overview. TJ target joint
1 The definition of a TJ has changed over time, but typically refers to 
the frequent occurrence of bleeding into a given joint within a rela-
tively short time period. The International Society on Thrombosis and 
Hemostasis (ISTH)-accepted definition of a TJ is considered to be a 
single joint into which three or more spontaneous bleeds occur within 
a consecutive 6-month period.
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are informed via background mortality rates (US life tables) 
[22].
2.4  Quality of Life Inputs
To incorporate changes in quality of life within the CEA, 
HRQoL data were sourced to inform the model. Health state 
utility values were incorporated via a multivariate Poisson 
regression analysis by O’Hara et al. [23]. The regression 
included covariates for the presence of TJs, age, and country 
(the UK, France, Germany, Spain, and Italy). For the pur-
pose of this analysis, patients from Germany were assumed 
to serve as a proxy for the US, and the impact on results 
when considering each of the other four countries was 
explored within sensitivity analysis. As age and TJ status 
influence utility, there are no fixed health state utility values 
provided within the model. However, for every year a patient 
ages, utility is expected to fall by 0.005, and TJ status is 
associated with a decrement of 0.110.
Separate to the health state utilities, breakthrough bleed-
ing episodes were associated with a utility decrement. A 
utility decrement of 0.16 was estimated from Neufeld et al., 
and applied for an assumed bleed duration of 5 days per the 
published report by the Institute for Clinical and Economic 
Review of emicizumab for severe HA patients with inhibi-
tors [24, 25]. The utility decrement per bleed was adjusted 
according to age, using age-specific multipliers [26].
Treatment with  Eloctate® has been shown to be asso-
ciated with an improvement in modified hemophilia joint 
health score (mHJHS) of 4.1 points [9]. To capture the 
impact of utility on changes in mHJHS, a persistent utility 
benefit of 0.012 (i.e., 0.01 per unit increase in the mHJHS) 
was assigned to patients treated with  Eloctate® (and set to 0 
for all other treatments) [27]. This was included to capture 
utility benefits associated with joint health outside of resolv-
ing TJs alone.
2.5  Cost Inputs
Only product acquisition costs (including excess factor 
product consumption) were included within the analysis, 
as all other medical resource use was expected to be rea-
sonably similar between alternative treatments (consistent 
with the approach taken in other previous economic evalu-
ations of rFVIII therapies in the SHA population [17, 28]). 
Healthcare utilization costs were captured in the Institute for 
Clinical and Economic Review’s assessment of emicizumab 
for patients with inhibitors, yet these were assumed equal 
between prophylaxis regimens and therefore not considered 
within the current analysis.
As all included treatments are dosed according to patient 
weight, age-specific weight data for the US HA population 
were used to inform the model. These data were taken from the 
aforementioned Institute for Clinical and Economic Review 
report. To determine the total weekly consumption of each 
product, the average dose per administration was multiplied by 
the frequency of administration per week and patient weight.
The average dose per administration for each product used 
to inform the analysis is presented in Table 2, alongside the 
cost per international unit (IU) and the available vial sizes/
potencies. Unit costs were taken from  AnalySource® [29]. 
Excess consumption was costed by rounding each adminis-
tration to the nearest 250-IU vial. Costs were taken for the 
year 2020.
To resolve breakthrough bleeding episodes, episodic 
rFVIII treatment may be required. All bleeds were assumed 
to be treated (as treated versus untreated bleeds were not 
explicitly reported in each of the clinical trials used to 
inform the model). Breakthrough bleeds were assumed to 
be treated with the prophylaxis regimen used. The dose of 
rFVIII to resolve each bleed was assumed to be 50.0 IU per 
kg for all prophylaxis regimens.
3  Results
3.1  Headline Model Results
Table 3 presents the headline results of the CEA. Compared 
with PEG-rFVIII, rFVIIIFc provided more QALYs (27.922 
versus 27.454) at a lower cost (2020 US$18.235 million 
versus US$20.198 million). This means that rFVIIIFc 
Table 1  Annualized bleeding rates for each prophylaxis regimen
ABR annualized bleeding rate, PEG-rFVIII PEGylated rFVIII, PK pharmacokinetic, PRO prophylaxis, rFVIII recombinant Factor VIII, rFVIIIFc 
rFVIII Fc-fusion protein, SHL standard half-life
Treatment Median ABR Source
Pediatrics Adults Pediatrics Adults
rFVIIIFc 1.6 0.7 ASPIRE (Nolan 2020, [18]) individualized 
PRO arm, Kids A-LONG cohort
ASPIRE (Nolan 2020, [18]) individualized PRO 
arm, A-LONG cohort
PEG-rFVIII 2.0 1.9 Study 261202 (Adynovate EPAR) PROLONG-ATE (Konkle 2015, [13]) PRO arm
SHL rFVIII 4.4 2.0 Blanchette 2008, modified prophylaxis arm Valentino 2012, ‘adherent’ PK-tailored prophylaxis
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dominates PEG-rFVIII (i.e., provides more QALYs at a 
reduced cost). The key driver of the difference in QALYs 
was the improvement in the mHJHS and modeled ABR 
(given that TJ resolution was similar across both treatment 
arms); whereas the difference in the costs of each proph-
ylaxis regimen led to large cost savings associated with 
rFVIIIFc.
Compared with SHL rFVIII, rFVIIIFc also provided more 
QALYs (27.922 versus 27.071) at similar, though slightly 
lower costs (US$18.235 million versus US$18.285 million). 
The QALY gain in this comparison is larger owing to the 
relatively greater improvement in terms of ABR, as well as 
the increased risk of TJ development for patients treated with 
SHL rFVIII. Costs were similar in this comparison owing 
to the trade-off between the per-unit cost of each product, 
versus the number of units required per week.
3.2  Sensitivity Analyses
Owing to the correlation between several key model param-
eters that were estimated in isolation from each other 
(e.g., ABR values for separate interventions), a traditional 
one-way sensitivity analysis (OWSA) was not performed. 
Instead, a series of deterministic scenario analyses were 
undertaken to more appropriately explore the impact of 
varying key model settings and assumptions on the results 
(presented in Table 4).
Sensitivity analyses explored the impact of reducing the 
duration of a bleed from 5 to 2 days, and increasing it to 
7 days. Reducing the duration led to an increase in total 
QALYs for all arms (and vice versa for the 7-day scenario), 
however the overall conclusions remained unchanged. Simi-
lar findings were shown when varying the magnitude of the 
disutility, instead of varying the duration over which it was 
applied.
In the base-case analysis, Germany was selected as a 
proxy country to inform estimation of utility values. In sce-
nario analyses, the region coefficient for the other four coun-
tries was applied, which caused the total QALY gains to vary 
markedly; however, the incremental QALY gain between 
treatments was essentially unchanged.
Limited data are available to inform the model transition 
probabilities (i.e., the development or resolution of TJs), 
Table 2  Costs for each prophylaxis regimen
IU international unit(s), kg kilogram(s), PEG-rFVIII PEGylated rFVIII, PK pharmacokinetic, PRO prophylaxis, rFVIII recombinant Factor VIII, 
rFVIIIFc rFVIII Fc-fusion protein, SHL standard half-life
a All products possible to dose in combinations of 250-IU vials, which is assumed to be the smallest denomination for the purpose of estimating 
drug costs
b Mid-point of range of SHL rFVIII costs applied in base-case analysis
c Based on reported annual consumption
d Estimated ratio of dose between PEG-rFVIII and SHL rFVIII in adults applied to value calculated for SHL rFVIII (based on Blanchette et al. 
[32])
Treatment Unit  costa Source(s)
rFVIIIFc US$2.23 per IU AnalySource® [29]
PEG-rFVIII US$2.16 per IU
SHL  rFVIIIb US$1.73 per IU
Treatment Weekly adult dose Source(s)
rFVIIIFc 80.7 IU per kg A-LONG  CSRc
PEG-rFVIII 91.4 IU per kg Estimated from Schwartz et al., [30]
SHL rFVIII 99.6 IU per kg Valentino et al., (2012), PK-tailored 
 prophylaxisc [31]
Treatment Weekly pediatric dose Source(s)
rFVIIIFc 93.0 IU per kg Kids A-LONG  CSRc
PEG-rFVIII 97.3 IU per kg Assumptiond
SHL rFVIII 108.4 IU per kg Calculated from Blanchette et al., 
[32]
Table 3  Headline cost-effectiveness analysis results
ICER incremental cost-effectiveness ratio, m million(s), PEG-rFVIII 
PEGylated rFVIII, rFVIII recombinant Factor VIII, rFVIIIFc rFVIII 
Fc-fusion protein, QALY quality-adjusted life-year, SHL standard 
half-life
Arm Costs QALYs ICER
rFVIIIFc US$18.235m 27.922
SHL rFVIII US$18.285m 27.071 rFVIIIFc dominates
PEG-rFVIII US$20.198m 27.454 rFVIIIFc dominates
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and so sensitivity analysis was performed to establish the 
impact of varying these assumptions. The scenarios explored 
included assuming no TJ resolution (0% probability) for all 
arms, complete TJ resolution (100% probability) within the 
first year for all arms, or an assumed probability of TJ devel-
opment (1% probability) for all arms per year. As with the 
other scenarios explored, the findings of these analyses were 
also consistent with the base-case results.
Table 4  Sensitivity analysis 
results
EHL extended half-life, m million(s), PEG-rFVIII PEGylated rFVIII, rFVIII recombinant Factor VIII, 
rFVIIIFc rFVIII Fc-fusion protein, QALY quality-adjusted life-year, SHL standard half-life, TJ(s) target 
joint(s)
Scenario Arm Costs (US$) QALYs
Bleed day = 2 days rFVIIIFc 18.235m 27.958
SHL rFVIII 18.285m 27.172
PEG-rFVIII 20.198m 27.550
Bleed day = 7 days rFVIIIFc 18.235m 27.898
SHL rFVIII 18.285m 27.003
PEG-rFVIII 20.198m 27.390
Bleed disutility = 80% of base-case value rFVIIIFc 18.235m 27.934
SHL rFVIII 18.285m 27.105
PEG-rFVIII 20.198m 27.486
Bleed disutility = 120% of base-case value rFVIIIFc 18.235m 27.910
SHL rFVIII 18.285m 27.037
PEG-rFVIII 20.198m 27.422
Utility analysis proxy country set to France rFVIIIFc 18.235m 24.995
SHL rFVIII 18.285m 24.109
PEG-rFVIII 20.198m 24.524
Utility analysis proxy country set to Italy rFVIIIFc 18.235m 28.073
SHL rFVIII 18.285m 27.243
PEG-rFVIII 20.198m 27.606
Utility analysis proxy country set to Spain rFVIIIFc 18.235m 24.151
SHL rFVIII 18.285m 23.265
PEG-rFVIII 20.198m 23.681
Utility analysis proxy country set to UK rFVIIIFc 18.235m 20.514
SHL rFVIII 18.285m 19.628
PEG-rFVIII 20.198m 20.044
No TJ resolution for all arms rFVIIIFc 18.235m 25.756
SHL rFVIII 18.285m 24.515
PEG-rFVIII 20.198m 25.299
Total TJ resolution for all arms rFVIIIFc 18.235m 27.923
SHL rFVIII 18.285m 27.178
PEG-rFVIII 20.198m 27.465
1% development of TJs per year for all arms rFVIIIFc 18.235m 27.891
SHL rFVIII 18.285m 27.392
PEG-rFVIII 20.198m 27.418
Upper bound cost for SHL rFVIII rFVIIIFc 18.235m 27.922
SHL rFVIII 18.708m 27.071
PEG-rFVIII 20.198m 27.454
Lower bound cost for SHL rFVIII rFVIIIFc 18.235m 27.922
SHL rFVIII 17.862m 27.071
PEG-rFVIII 20.198m 27.454
Once-weekly dosing for EHL rFVIII therapies rFVIIIFc 18.083m 27.922
SHL rFVIII 18.285m 27.071
PEG-rFVIII 20.026m 27.454
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Additional scenarios were considered varying the per-
unit price of SHL rFVIII therapies, reflective of the range 
of options currently available to patients in practice. When 
considering the lower bound price (equivalent to US$1.69 
per IU), rFVIIIFc was associated with incremental costs in 
the region of US$373,000. However, when using the upper 
bound cost of US$1.77 per IU, the cost savings estimated 
in the base-case analysis increased further to US$473,000.
Finally, a scenario analysis was conducted to explore the 
impact in results if rFVIIIFc and PEG-rFVIII were admin-
istered once per week (instead of twice weekly per the base-
case analysis), but with the same overall factor consumption. 
Both of these products may be used with a relatively longer 
time period (versus SHL rFVIII) between administrations, 
owing to their EHL. The reduced frequency of administra-
tion leads to further cost savings due to less excess rFVIII 
consumption.
4  Discussion
This study presents the results of a CEA (based on a previ-
ously published economic model) comparing three alterna-
tive rFVIII prophylaxis treatments for adults with severe 
HA without inhibitors. The results of the base-case analy-
sis demonstrate that rFVIIIFc is expected to provide more 
QALYs than its comparators, and is associated with cost 
savings.
In the non-inhibitor severe HA population, previously 
published studies have explored the cost effectiveness of 
alternative rFVIII regimens, though typically these have 
comprised a single comparison [17, 28, 33]. However, to 
date (and to the authors’ knowledge) no formal cost-utility 
comparisons between EHL rFVIII prophylaxis regimens 
have been conducted, and therefore this was the focus of 
our study.
Sensitivity analyses were conducted to explore the impact 
of alternative model settings and assumptions, as well as 
the choice of data source(s) on results. In general, the over-
all findings of the base-case analysis were unchanged when 
varying assumptions. However, costs were found to be most 
sensitive to acquisition costs, weight, and dosing assump-
tions; with QALYs most sensitive to the application of 
improved joint health via the mHJHS.
The lack of available data regarding joint health is a key 
limitation of this analysis. Until recently, prevention of joint 
damage was not considered a primary goal of treatment, 
as historical treatment strategies focused predominantly on 
the prevention of bleeding episodes. Following the success 
of routine prophylaxis in preventing breakthrough bleeds, 
preservation of joint health has become an achievable goal 
of treatment, and therefore is also an increasingly relevant 
outcome measure in contemporary trials. Further evidence 
collection is planned concerning long-term joint health 
outcomes, which may facilitate an update to this CEA to 
include other aspects of joint health (for instance, cost sav-
ings through avoided surgeries). Such data collection may, in 
principle, also allow for the development of a more complex 
model structure (e.g., a simulation model), which is not pos-
sible to robustly develop with current data.
In April 2018, the Institute for Clinical and Economic 
Review published its review of emicizumab  (Hemlibra®, 
Roche) for the treatment of severe HA patients with inhibi-
tors [24]. The review found emicizumab use led to cost 
savings with improved clinical outcomes versus prophy-
laxis with bypassing agents in the severe HA population of 
patients with inhibitors. However, the scope of the review 
was restricted to the inhibitor population only (in line with 
the license for emicizumab at the time this review was 
conducted).
More recently, in August 2020, the Institute for Clini-
cal and Economic Review published its draft assessment 
of valoctocogene roxaparvovec  (Roctavian®, BioMarin) 
and emicizumab for the non-inhibitor population [34]. 
However, conducting a comparison between valoctoco-
gene roxaparvovec, emicizumab, and rFVIII products 
is challenging, in light of varying product profiles and 
the relatively limited evidence on these products for a 
robust and balanced comparison between these treatment 
options. Therefore, a comparison between rFVIII prod-
ucts and other non-rFVIII products was not considered in 
this study, but may be possible to consider in the future.
Medical resource costs not related to product acquisi-
tion were omitted from the CEA as there are no major 
differences expected between the management of patients 
treated with alternative treatments. However, patients 
with a lower ABR would theoretically have a lower medi-
cal resource use cost, and so the cost effectiveness of 
treatments that reduce ABR may be underestimated by 
our analysis (due to medical resource use cost savings not 
captured by the model).
A further limitation of the study is that the acquisi-
tion costs for each product may be subject to a number 
of confidential pricing agreements, and were therefore 
not captured within the CEA. In lieu of average sales 
prices (ASPs) to inform the CEA, wholesale acquisition 
costs (WACs) were used. Consequently, the ‘true’ cost 
effectiveness of alternative treatments may be affected if 
the CEA is informed by the ‘true’ acquisition costs (i.e., 
ASPs instead of WACs). This remains a key limitation 
of the findings of this study, and indeed of other CEAs 
conducted in the severe HA population based on publicly 
available data.
The available data to inform the CEA is predominantly 
based on studies in adult patients. While there are pedi-
atric studies for rFVIIIFc and PEG-rFVIII, at the time 
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of the analyses there were no available studies for emi-
cizumab or valoctocogene roxaparvovec (though emici-
zumab is licensed for use in ages newborn and older) 
[35]. In practice, pediatric patients are expected to be 
monitored more closely than adults, given that effec-
tive management in the early years of life is associated 
with substantially reduced risk of longer-term complica-
tions (e.g., joint damage). The focus of this CEA was 
on comparisons where pediatric data were available, in 
order to estimate the lifetime costs and effects associated 
with alternative treatments. Further evidence collection 
is required in order to establish the cost effectiveness of 
other treatments.
The impact of breakthrough bleeding episodes is 
expected to also affect caregivers—both in terms of finan-
cial burden and quality of life. Impacts on caregivers were 
not captured within the CEA for the same reason that 
medical resource costs were not included (i.e., no major 
differences expected between treatments), and also in 
acknowledgement of pediatric patients being the primary 
recipients of informal care. Nevertheless, the burden of 
sub-optimal management for severe HA patients on car-
egivers is an important consideration when determining 
the most appropriate treatment for a given patient.
5  Conclusions
This study builds upon a previously published CEA in SHA 
to facilitate comparisons of contemporary rFVIII treatment 
options for adults with severe HA, without the presence of 
inhibitors. The model utilizes available data concerning joint 
health, dosing, and rates of breakthrough bleeding in order 
to capture multiple aspects of the disease and its impact on 
patients. Based on the findings of this analysis, rFVIIIFc 
may offer a clinically and cost-effective option for patients 
with severe HA, especially compared with PEG-rFVIII, with 
cost savings in the region of US$2 million over a lifetime 
horizon.
The key limitation of the CEA is a lack of data availabil-
ity to fully capture changes in joint health over time, and 
how products compare within a head-to-head trial setting. 
Further to this, like many other previously developed eco-
nomic evaluations, the model does not capture the develop-
ment of inhibitors. Further research that encompass the full 
range of impacts on joint health and the risk of inhibitor 
development, especially within the context of a pediatric 
population, is warranted to expand upon the current CEA 
analysis.
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